Login to Your Account


GSK to Shine Light on Raw Clinical Trial Data

By Marie Powers
Staff Writer

Friday, October 12, 2012

GlaxoSmithKline plc (GSK) took extraordinary steps toward data transparency Thursday, disclosing plans to accelerate its "open innovation" approach to R&D by allowing researchers access to detailed patient-level data underlying clinical trials both in approved medicines and failed investigational compounds.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription